Christine Campbell
YOU?
Author Swipe
View article: Cervical high-risk human papillomavirus infection and its associated risk factors: a community-based cross-sectional study in hard-to-reach areas in Bangladesh
Cervical high-risk human papillomavirus infection and its associated risk factors: a community-based cross-sectional study in hard-to-reach areas in Bangladesh Open
Objectives This study aimed to determine the prevalence of cervical high-risk human papillomavirus (hrHPV) in a community-based setting and its risk factors association in women living in hard-to-reach areas in Bangladesh. Design A cross-s…
View article: Thermal‐Infrared Measurements of the North‐East Tower at Ardrossan Castle
Thermal‐Infrared Measurements of the North‐East Tower at Ardrossan Castle Open
Thermal‐infrared imaging of buildings is used to investigate a range of phenomena including the accumulation of moisture. In general, the presence of moisture poses a direct danger to historic structures and must be characterized prior to …
View article: Cancer Incidence Among People With a Prior Hospital Record of Depression in Scotland, 1991–2019: A Cohort Study
Cancer Incidence Among People With a Prior Hospital Record of Depression in Scotland, 1991–2019: A Cohort Study Open
Objective Current evidence on the association between depression and cancer risk is conflicting, with little understanding of how associations vary by time period or sociodemographic factors. We aimed to compare cancer incidence in people …
View article: Living With and Beyond Cancer With Comorbid Conditions: Qualitative Insights to Understand Psychosocial Support Needs
Living With and Beyond Cancer With Comorbid Conditions: Qualitative Insights to Understand Psychosocial Support Needs Open
Introduction There is a pressing need to understand and explore the complex experiences and psychosocial support needs of people LWBC‐CM and their informal caregivers, to inform survivorship and supportive care interventions. Methods In‐de…
View article: Understanding cervical cancer awareness in hard-to-reach areas of Bangladesh: A cross-sectional study involving women and household decisionmakers
Understanding cervical cancer awareness in hard-to-reach areas of Bangladesh: A cross-sectional study involving women and household decisionmakers Open
Introduction In Bangladesh, the uptake of cervical cancer screening is low. Lack of knowledge and understanding of symptoms and risk factors contributes to low screening uptake. The purpose of this study was to explore the knowledge of cer…
View article: Reviewer #1 (Public Review): Opposing, spatially-determined epigenetic forces impose restrictions on stochastic olfactory receptor choice
Reviewer #1 (Public Review): Opposing, spatially-determined epigenetic forces impose restrictions on stochastic olfactory receptor choice Open
Olfactory receptor (OR) choice represents an example of genetically hardwired stochasticity, where every olfactory neuron expresses one out of ∼2000 OR alleles in a probabilistic, yet stereotypic fashion. Here, we propose that topographic …
View article: Reviewer #3 (Public Review): Opposing, spatially-determined epigenetic forces impose restrictions on stochastic olfactory receptor choice
Reviewer #3 (Public Review): Opposing, spatially-determined epigenetic forces impose restrictions on stochastic olfactory receptor choice Open
Olfactory receptor (OR) choice represents an example of genetically hardwired stochasticity, where every olfactory neuron expresses one out of ∼2000 OR alleles in a probabilistic, yet stereotypic fashion. Here, we propose that topographic …
View article: Opposing, spatially-determined epigenetic forces impose restrictions on stochastic olfactory receptor choice
Opposing, spatially-determined epigenetic forces impose restrictions on stochastic olfactory receptor choice Open
Olfactory receptor (OR) choice represents an example of genetically hardwired stochasticity, where every olfactory neuron expresses one out of ~2000 OR alleles in a probabilistic, yet stereotypic fashion. Here, we show that topographic res…
View article: Supplementary Table S1 from High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Supplementary Table S1 from High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab Open
Supplementary Table S1. Multivariate Models in the IHC 3+ Subgroup
View article: Data from High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Data from High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab Open
Purpose: Expression of p95HER2 has been associated with resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Conversely, high levels of HER2 have been linked with increased clinical benefit from anti-HER2 ther…
View article: Figure S1 from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Figure S1 from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial Open
Illustration of droplet digital PCR (ddPCR)-based PIK3CA H1047L and E545K mutation detection in serial dilutions. A. Representative 1-D plot of ddPCR reactions. The ordinate scales indicate fluorescent amplitude according to FAM (6-Carboxy…
View article: Figure S2 from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Figure S2 from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial Open
Forest plots for the test of association between ctDNA and (A) pCR or (B) event-free survival. All tests are corrected for clinic-pathological characteristics. ctDNA: circulating tumor DNA; VAF: variant allele fraction; OR: odds ratio, HR:…
View article: Supplementary Table S1 from High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Supplementary Table S1 from High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab Open
Supplementary Table S1. Multivariate Models in the IHC 3+ Subgroup
View article: Data from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Data from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial Open
Purpose:In the neoadjuvant treatment (NAT) setting, dual HER2-targeted therapy is associated with increased pathologic complete response (pCR) rates compared with each therapy alone. Biomarkers allowing to predict treatment response during…
View article: Figure S3 from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Figure S3 from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial Open
Forest plots for the test of association between changes between baseline and week 2 in ctDNA detection, tested either by taking differences for continuous variables or by taking subgroups of patients who had detectable ctDNA at baseline o…
View article: Supplementary Figure S1 from High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Supplementary Figure S1 from High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab Open
Supplementary Figure S1. Distribution of HER2 expression (measured by HERmark) in all patients (left) and in 3+ IHC cohort patients (right). All patient: n=324; IHC3+: n=232.
View article: Figure S2 from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Figure S2 from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial Open
Forest plots for the test of association between ctDNA and (A) pCR or (B) event-free survival. All tests are corrected for clinic-pathological characteristics. ctDNA: circulating tumor DNA; VAF: variant allele fraction; OR: odds ratio, HR:…
View article: Supplementary Data from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Supplementary Data from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial Open
Supplementary materials and methods
View article: Figure S1 from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Figure S1 from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial Open
Illustration of droplet digital PCR (ddPCR)-based PIK3CA H1047L and E545K mutation detection in serial dilutions. A. Representative 1-D plot of ddPCR reactions. The ordinate scales indicate fluorescent amplitude according to FAM (6-Carboxy…
View article: Data from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Data from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial Open
Purpose:In the neoadjuvant treatment (NAT) setting, dual HER2-targeted therapy is associated with increased pathologic complete response (pCR) rates compared with each therapy alone. Biomarkers allowing to predict treatment response during…
View article: Supplementary Tables from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Supplementary Tables from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial Open
Supplementary Tables
View article: Supplementary Tables from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Supplementary Tables from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial Open
Supplementary Tables
View article: Figure S3 from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Figure S3 from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial Open
Forest plots for the test of association between changes between baseline and week 2 in ctDNA detection, tested either by taking differences for continuous variables or by taking subgroups of patients who had detectable ctDNA at baseline o…
View article: Data from High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Data from High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab Open
Purpose: Expression of p95HER2 has been associated with resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Conversely, high levels of HER2 have been linked with increased clinical benefit from anti-HER2 ther…
View article: Supplementary Figure S1 from High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Supplementary Figure S1 from High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab Open
Supplementary Figure S1. Distribution of HER2 expression (measured by HERmark) in all patients (left) and in 3+ IHC cohort patients (right). All patient: n=324; IHC3+: n=232.